Can PSMA-Targeting PET/CT Be a Valuable Instrument to Assess the Presence of Brain Metastases in Lung Cancer Patients?: A Case Report. (24th June 2023)

• Record Type: Journal Article
• Authors: Dall'Armellina, Sara; Cauda, Simona; Duca, Sergio; Gasparro, Martina; Racca, Manuela
• Is Part Of: Clinical nuclear medicine. Volume 48:Number 6(2023)
• Page Start: e304
• Page End: e306
• Publication Date: 2023-06-24
• Subjects: 18F-PSMA PET/CT -- brain metastasis -- pitfall -- primary lung cancer; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004675
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: A 78-year-old man with synchronous diagnosis of prostate cancer and lung adenocarcinoma was referred to our institute for prostate cancer staging with [ 18 F]F–prostate-specific membrane antigen (PSMA) 1007 PET/CT. In addition to the previously known lesion of the right lung, PSMA-targeted PET/CT highlighted 2 areas of abnormal uptake in the brain, in the left frontal and temporal lobes. A subsequent MRI confirmed the lesions observed on PET/CT. Because PSMA-targeting radiopharmaceuticals do not accumulate in healthy brain parenchyma, and recent literature reported promising performances of PSMA-targeted PET/CT in gliomas and metastases from tumors other than prostate cancer, this employment of PSMA radioligands needs to be further explored.